As biologics and novel modalities become increasingly sophisticated, understanding molecular structure under controlled conditions tells only part ...
For emerging biopharma companies, speed, quality and scalability cannot be treated as separate priorities. As products progress t...
As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of ther...
As advanced therapies move from development towards commercial scale, quality is becoming far more than a regulatory checkpoint. It is increasingly...
Early detection remains one of the biggest challenges in cancer care, particularly for ovarian cancer, where symptoms can be difficult to r...
The development of cannabinoid and psychedelic medicines is entering a more evidence-driven phase, with clinical validation, safety, regulatory a...
At INTERPHEX, sustainability and supply chain performance emerged as important priorities for pharmaceutical packaging. John Jansen, Head of Global Marketi...
As AI and digital technologies increasingly influence pharmaceutical development, CDMOs are taking on a broader role in helping sponsors im...
As breast imaging continues to evolve toward more quantitative and patient-centred approaches, QT Imaging is developing a three-dimensional ultraso...
Drug development is inherently uncertain, with scientific discoveries, manufacturing challenges, regulatory expectations and commercial priorities ...
Bone Biologics is developing a targeted approach to bone regeneration through its proprietary NELL-1 platform, designed to address the li...
Q2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the...
Merck has reported strong financial results for the second quarter of 2026, driven by sustained growth across its Life Science and Electronics businesses...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced financial results...
© 2026 Biopharma Boardroom. All Rights Reserved.
